AZ halted DAPA-CKD in July after revealing that Farxiga (dapagliflozin) met its objective of slowing the worsening of renal function and cut the risk of death in patients with chronic kidney ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback